Oncology

Join community oncology colleagues for a free webinar covering ESR1-mutated breast cancer biomarker testing, how estrogen receptor-targeted therapies compare, and practical guidance on patient selection and safety in everyday practice. Pick your date: September 10, 14, or 30. Register now!

Hear practical clinical insights on evolving first-line management approaches for patients with PV. Watch the video now. 

ADC-associated ILD/pneumonitis can present with subtle symptoms or imaging findings that are easy to overlook. In this video, a medical oncologist and radiologist review risk factors, early imaging signals, and multidisciplinary management. Watch now!

Explore expert-led education on subcutaneous immunotherapy in genitourinary cancers through 4 videos, an article, an infographic, and quizzes. Review the evidence, patient experience, and practice implications in the format that fits you best. Start learning! 

Managing hepatocellular carcinoma (HCC) means balancing tumor control against a liver that may already be failing. Pierre Gholam, MD, explains why Child-Pugh (CP) and ALBI scores together offer a more complete picture of hepatic reserve than either tool alone, and why treating CP-B as a uniform group can lead to misjudged prognosis and treatment decisions. Watch Now.

Short on time? In under 10 minutes, hear Beth Faiman, PhD, MSN, APN-BC, AOCN, and Donna Catamero, MSN, ANP-BC, OCN, discuss practical perspectives on CAR T–cell therapy referral and patient selection and improving access to care in multiple myeloma. Catch the highlights on demand!

Listen as an expert discusses where delta-like ligand 3 (DLL3) may fit within the evolving biomarker journey for extrapulmonary neuroendocrine carcinomas (epNEC), including practical considerations for tissue stewardship, biomarker assessment, and multidisciplinary care.

Choose from a 4-part video series, an article, or an infographic to explore expert perspectives on subcutaneous immuno-oncology in metastatic melanoma. Review the evidence and practical treatment considerations in the format that best fits your learning style. View now!

Survival gains are reproducible in refractory metastatic colorectal cancer (mCRC), yet key biological questions remain. Are we modulating the tumor microenvironment, or fundamentally altering how the tumor behaves? Watch expert faculty debate the evidence and its implications for future therapeutic strategy.